You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -340.6% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -2.9 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 15.8 | n/a |
Price / Book value | 27.6 |
Latest | Forecast | |
---|---|---|
Revenue | -37.7% | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-05-31 | 0.17 | -8.55 | -12.97p | -7.1 | 0.0 | n/a | n/a | 0.0% |
2020-05-31 | 0.51 | -9.78 | -13.36p | -8.3 | 0.0 | n/a | n/a | 0.0% |
2021-05-31 | 3.72 | -6.06 | -7.73p | -27.0 | 0.0 | n/a | n/a | 0.0% |
2022-08-31 | 2.32 | -6.58 | -7.91p | -11.2 | 0.0 | n/a | n/a | 0.0% |
2023-08-31 | 1.15 | -5.93 | -8.47p | -2.7 | 0.0 | n/a | n/a | 0.0% |
Oncimmune revenue falls as it implements new strategy Sharecast News | 29 Feb |
---|---|
Oncimmune sells 'non-core' lung and antibody assets in £13m deal Sharecast News | 22 May |
Result of General Meeting | 03-Apr-24 00:00 |
---|---|
Total Voting Rights | 03-Apr-24 00:00 |
Holding(s) in Company | 26-Mar-24 11:19 |
Block Listing Return | 13-Mar-24 17:37 |
Posting of Notice of General Meeting | 06-Mar-24 15:05 |